United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
United Therapeutics Corporation Announces FDA Approval of the LungFX Device for Centralized Ex Vivo Lung Perfusion
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
MannKind Announces Ralinepag Dry Powder Inhalation Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
Heritage Confirms High-Grade Gold Mineralization at The Melba Project Returning 15.57g/t Au over 9m from 43m, Including: 28.98g/t Au over 4.80m
First Three Holes of a 20,000-Meter Program Just Pushed a U.S. Antimony-Gold Resource Beyond Its Own Boundaries
RETRANSMISSION: QIMC Drills New Company Record of 27.8% Clean Natural Hydrogen at Just 374 Metres at Bennett Hill, Nova Scotia
